相关实验视频
Updated: May 13, 2025

Predictive Immune Modeling of Solid Tumors
Published on: February 25, 2020
iMLGAM:集成机器学习和基因算法驱动的多态学分析,用于预测泛癌免疫疗法反应
Bicheng Ye1, Jun Fan2, Lei Xue2
1Liver Disease Center of Integrated Traditional Chinese and Western Medicine, Department of Radiology, Zhongda Hospital, Medical School Southeast University, Nurturing Center of Jiangsu Province for State Laboratory of AI Imaging & Interventional Radiology (Southeast University) Nanjing China.
我们创建了一个R包,iMLGAM,用多omics数据预测免疫检查点阻塞 (ICB) 治疗反应. 较低的iMLGAM分数预测了更好的治疗结果,并将中体蛋白55 (CEP55) 确定为改善癌症免疫治疗的目标.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 生物信息学是一种生物信息学.
背景情况:
- 免疫检查点阻塞 (ICB) 治疗的有效性在患者之间有很大差异.
- 预测生物标志物对于优化ICB治疗策略至关重要.
研究的目的:
- 开发一个先进的多omics数据集成工具,用于预测ICB治疗结果.
- 确定新的分子标,以提高ICB的疗效.
主要方法:
- 开发集成的机器学习和基因算法驱动的多态学分析 (iMLGAM) R包.
- 在独立患者队列中验证iMLGAM得分.
- 集群定期间隔的简短的平行体重复 (CRISPR) 选,以确定关键的调节分子.
主要成果:
- 与现有的生物标志物相比,iMLGAM评分显示了ICB治疗反应的优异预测性能.
- 较低的iMLGAM分数与增强的治疗反应和有利的瘤免疫微环境显著相关.
- 中体蛋白55 (CEP55) 被确定为瘤免疫逃避的关键媒介.
结论:
- iMLGAM包为个性化癌症免疫疗法预测提供了一个强大的工具.
- CEP55代表了一个有前途的治疗目标,可以克服对ICB治疗的耐药性.
- 这些发现为改善癌症免疫疗法患者治疗结果提供了新的策略.
更多相关视频
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
相关概念视频
Tumor Immunotherapy
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...